EU orders US biotech firms to unwind $7 bn merger

The European Commission on Thursday ordered US biotech giant Illumina to unwind its $7 billion purchase of cancer test pioneer GRAIL that it argues stifles competition in a key emerging public health domain.

This post was originally published on this site